(Source: United Daily 2015-03-06）
PBF recently signed a contract with WEGO Group, one of the top 10 pharmaceutical companies in China, to form a joint venture. The new business will engage in the launch of Nephoxil in China, including license application, importation, production and marketing/sales.
According to PBF, Nephoxil was licensed by the Taiwanese authority on Jan. 15, 2015. The company is keen to apply for NHI reimbursement. Nephoxil is for treating the symptoms of hyperphosphatemia commonly in dialysis patients. It can help cut the NHI spending by reducing the use of erythropoietin and IV iron infusions.
The population of patients in need of dialysis treatment is increasing in Taiwan, as well as in China. China has the world’s third largest population of end-stage dialysis patients. The number is 230,000 at present, and is expected to grow to 1.5 million in 2020.
Chiang Ming-Zong, the general manager of PBF, expressed that Nephoxil is expected to reach the market in Taiwan later this year. The company is now filing the NDA in the EU, and plans to enter the markets in the US and Japan. PBF has high hope for Nephoxil, which may also open a new page in the history of the biotech industry in Taiwan.
(Translated by TRPMA)
More Information on United Daily